- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Melanoma
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 711KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 132KB)
Nivolumab plus ipilimumab – November 2022
Nivolumab plus Ipilimumab: Nivolumab: Injection concentrate for I.V. infusion 100 mg in 10 mL, Injection concentrate for I.V. infusion 40 mg in 4 mL; Opdivo®. Ipilimumab: Injection concentrate for I.V. infusion 200 mg in 40 mL, Injection concentrate
Last updated
3 March 2023
